Radiotherapy plus razoxane for advanced limited extent carcinoma of the lung.

Abstract

Forty-four patients with limited extent American Joint Committee on Cancer Stage II-III non-small cell carcinoma of the lung were randomly assigned to potentially curative radiation therapy plus one of two schedules of razoxane. The weekly schedule was 1 gram per square meter body surface area (BSA) every 8 hours for two doses per week, and the daily schedule was a fixed dose of 250 mg per day. The 50% Kaplan-Meier survival estimate for both groups combined was 9 months. There was no survival difference between the two dose-schedules. Toxicity was formidable with an 82% incidence of esophagitis, and a 20% incidence of grade III-IV esophagitis. Fifty-nine percent of patients developed hematologic toxicity. This was greater with the weekly dose-schedule (P = 0.01). Forty-one percent of patients developed radiographic or symptomatic pneumonitis. One patient developed a fatal myelitis. This program is no more effective than irradiation alone, and has substantial morbidity.

• Authors: M P Corder, H H Tewfik, G H Clamon, C E Platz, J T Leimert, K D Herbst, J E Byfield
• Journal: Cancer (Cancer) Vol. 53 Issue 9 Pg. 1852-6 (May 01 1984) ISSN: 0008-543X [Print] United States
• PMID: 6322961 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Piperazines
• Razoxane

Topics

• Adenocarcinoma (drug therapy, mortality, radiotherapy)
• Adolescent
• Adult
• Aged
• Blood Cell Count
• Carcinoma, Small Cell (drug therapy, mortality, radiotherapy)
• Carcinoma, Squamous Cell (drug therapy, mortality, radiotherapy)
• Child
• Child, Preschool
• Clinical Trials as Topic
• Combined Modality Therapy
• Drug Administration Schedule
• Esophagitis (etiology)
• Female
• Humans
• Lung Neoplasms (drug therapy, mortality, radiotherapy)
• Male
• Middle Aged
• Piperazines (administration & dosage)
• Pneumonia (etiology)
• Radiation Injuries (etiology)
• Random Allocation
• Razoxane (administration & dosage, adverse effects)